Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post–Percutaneous Coronary Intervention (RIVER-PCI) trial
Background Incomplete revascularization (ICR) after percutaneous coronary intervention (PCI) is common and is associated with increased rates of rehospitalization, revascularization, and mortality. Adjunctive pharmacotherapy with ranolazine, an inhibitor of the late sodium current with anti-ischemic...
Gespeichert in:
| Veröffentlicht in: | The American heart journal 2013-12, Vol.166 (6), p.953-959.e3 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 959.e3 |
|---|---|
| container_issue | 6 |
| container_start_page | 953 |
| container_title | The American heart journal |
| container_volume | 166 |
| creator | Weisz, Giora, MD Farzaneh-Far, Ramin, MD Ben-Yehuda, Ori, MD DeBruyne, Bernard, MD Montalescot, Gilles, MD, PhD Lerman, Amir, MD Mahmud, Ehtisham, MD Alexander, Karen P., MD Ohman, E. Magnus, MD White, Harvey D., DSc Olmsted, Ann, PhD Walker, Gennyne A., PhD Stone, Gregg W., MD |
| description | Background Incomplete revascularization (ICR) after percutaneous coronary intervention (PCI) is common and is associated with increased rates of rehospitalization, revascularization, and mortality. Adjunctive pharmacotherapy with ranolazine, an inhibitor of the late sodium current with anti-ischemic properties, may be effective in reducing recurrent events after PCI in patients with ICR. Trial Design RIVER-PCI is a phase 3, randomized, double-blind, placebo-controlled, international event-driven clinical trial evaluating the efficacy of ranolazine in patients with a history of chronic angina and ICR after PCI. Approximately 2,600 participants with ICR post-PCI will be randomized in a 1:1 ratio to ranolazine or matched placebo within 14 days of an index PCI. The primary end point of the trial is time to the first occurrence of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization. Participants will be followed up for a minimum of 1 year and until at least 720 confirmed primary end point events have occurred. Secondary end points include sudden cardiac death, cardiovascular death, myocardial infarction, and measures of quality of life and cost-effectiveness. The evaluation of long-term safety will include all-cause mortality, stroke, transient ischemic attack, and hospitalization for heart failure. Enrollment commenced in November 2011 and was completed in summer 2013. Conclusions RIVER-PCI is a novel, large-scale, international, randomized, double-blind, placebo-controlled clinical trial evaluating the role of ranolazine in the long-term medical management of patients with ICR post-PCI. |
| doi_str_mv | 10.1016/j.ahj.2013.08.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1461878625</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002870313005280</els_id><sourcerecordid>1461878625</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-92eb44f2b0eab233816260298405eeede1940d0c166000b6f641e5cacecf89423</originalsourceid><addsrcrecordid>eNp9ksFuEzEQhlcIREvhAbggS1zKYcPY63gdkJBQKBCpElGgvVqOd5Y4OOtge4PaE-_AG_IMPAAOaUlVJE6W7e-f3zP-i-IxhQEFKp4vB3qxHDCg1QDkAIDfKQ4pjOpS1JzfLQ4BgJWyhuqgeBDjMm8Fk-J-ccA4E5KBPCx-nUUkviVBd97pS9shsR1Z62SxS5F8s2mRD4xfrR0mJAE3Opre6WAvM-M7otuEgawxmD7pDn0fifHBdzpcZGG-2-RCGXxB3mC0n7Oga7Lb9ki7P9ZpgWS2t299IJO94znGiI7M_jGe-ph-fv8xvek8vnae3HAmx7PJ-cmsnI4nz0gKVruHxb1Wu4iPrtaj4uztyafx-_L0w7vJ-PVpaXglUjliOOe8ZXNAPWdVJalgAthIchgiYoN0xKEBQ4XIo52LVnCKQ6MNmlaOOKuOiuNd3XXwX3uMSa1sNOjc7rmKckFlLQUbZvTpLXTp-5BHlKkhr6WUNa0yRXeUCT7GgK1aB7vKDSsKahsJtVQ5EmobCQVS5UhkzZOryv18hc1fxXUGMvByB2AexcZiUNHk3zfY2IAmqcbb_5Z_dUttnO2s0e4LXmDcd6EiU6A-bjO5jSStAIZMQvUbWlrjDA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1547888713</pqid></control><display><type>article</type><title>Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post–Percutaneous Coronary Intervention (RIVER-PCI) trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Weisz, Giora, MD ; Farzaneh-Far, Ramin, MD ; Ben-Yehuda, Ori, MD ; DeBruyne, Bernard, MD ; Montalescot, Gilles, MD, PhD ; Lerman, Amir, MD ; Mahmud, Ehtisham, MD ; Alexander, Karen P., MD ; Ohman, E. Magnus, MD ; White, Harvey D., DSc ; Olmsted, Ann, PhD ; Walker, Gennyne A., PhD ; Stone, Gregg W., MD</creator><creatorcontrib>Weisz, Giora, MD ; Farzaneh-Far, Ramin, MD ; Ben-Yehuda, Ori, MD ; DeBruyne, Bernard, MD ; Montalescot, Gilles, MD, PhD ; Lerman, Amir, MD ; Mahmud, Ehtisham, MD ; Alexander, Karen P., MD ; Ohman, E. Magnus, MD ; White, Harvey D., DSc ; Olmsted, Ann, PhD ; Walker, Gennyne A., PhD ; Stone, Gregg W., MD</creatorcontrib><description>Background Incomplete revascularization (ICR) after percutaneous coronary intervention (PCI) is common and is associated with increased rates of rehospitalization, revascularization, and mortality. Adjunctive pharmacotherapy with ranolazine, an inhibitor of the late sodium current with anti-ischemic properties, may be effective in reducing recurrent events after PCI in patients with ICR. Trial Design RIVER-PCI is a phase 3, randomized, double-blind, placebo-controlled, international event-driven clinical trial evaluating the efficacy of ranolazine in patients with a history of chronic angina and ICR after PCI. Approximately 2,600 participants with ICR post-PCI will be randomized in a 1:1 ratio to ranolazine or matched placebo within 14 days of an index PCI. The primary end point of the trial is time to the first occurrence of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization. Participants will be followed up for a minimum of 1 year and until at least 720 confirmed primary end point events have occurred. Secondary end points include sudden cardiac death, cardiovascular death, myocardial infarction, and measures of quality of life and cost-effectiveness. The evaluation of long-term safety will include all-cause mortality, stroke, transient ischemic attack, and hospitalization for heart failure. Enrollment commenced in November 2011 and was completed in summer 2013. Conclusions RIVER-PCI is a novel, large-scale, international, randomized, double-blind, placebo-controlled clinical trial evaluating the role of ranolazine in the long-term medical management of patients with ICR post-PCI.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2013.08.004</identifier><identifier>PMID: 24268208</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Acetanilides - therapeutic use ; Angina Pectoris - therapy ; Cardiology ; Cardiovascular ; Coronary vessels ; Double-Blind Method ; Enzyme Inhibitors - therapeutic use ; Female ; Heart attacks ; Hospitalization - statistics & numerical data ; Humans ; Male ; Mortality ; Percutaneous Coronary Intervention ; Piperazines - therapeutic use ; Quality of Life ; Ranolazine ; Retreatment - statistics & numerical data ; Treatment Outcome</subject><ispartof>The American heart journal, 2013-12, Vol.166 (6), p.953-959.e3</ispartof><rights>Mosby, Inc.</rights><rights>2013 Mosby, Inc.</rights><rights>2013.</rights><rights>Copyright Elsevier Limited Dec 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-92eb44f2b0eab233816260298405eeede1940d0c166000b6f641e5cacecf89423</citedby><cites>FETCH-LOGICAL-c436t-92eb44f2b0eab233816260298405eeede1940d0c166000b6f641e5cacecf89423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002870313005280$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24268208$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weisz, Giora, MD</creatorcontrib><creatorcontrib>Farzaneh-Far, Ramin, MD</creatorcontrib><creatorcontrib>Ben-Yehuda, Ori, MD</creatorcontrib><creatorcontrib>DeBruyne, Bernard, MD</creatorcontrib><creatorcontrib>Montalescot, Gilles, MD, PhD</creatorcontrib><creatorcontrib>Lerman, Amir, MD</creatorcontrib><creatorcontrib>Mahmud, Ehtisham, MD</creatorcontrib><creatorcontrib>Alexander, Karen P., MD</creatorcontrib><creatorcontrib>Ohman, E. Magnus, MD</creatorcontrib><creatorcontrib>White, Harvey D., DSc</creatorcontrib><creatorcontrib>Olmsted, Ann, PhD</creatorcontrib><creatorcontrib>Walker, Gennyne A., PhD</creatorcontrib><creatorcontrib>Stone, Gregg W., MD</creatorcontrib><title>Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post–Percutaneous Coronary Intervention (RIVER-PCI) trial</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Background Incomplete revascularization (ICR) after percutaneous coronary intervention (PCI) is common and is associated with increased rates of rehospitalization, revascularization, and mortality. Adjunctive pharmacotherapy with ranolazine, an inhibitor of the late sodium current with anti-ischemic properties, may be effective in reducing recurrent events after PCI in patients with ICR. Trial Design RIVER-PCI is a phase 3, randomized, double-blind, placebo-controlled, international event-driven clinical trial evaluating the efficacy of ranolazine in patients with a history of chronic angina and ICR after PCI. Approximately 2,600 participants with ICR post-PCI will be randomized in a 1:1 ratio to ranolazine or matched placebo within 14 days of an index PCI. The primary end point of the trial is time to the first occurrence of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization. Participants will be followed up for a minimum of 1 year and until at least 720 confirmed primary end point events have occurred. Secondary end points include sudden cardiac death, cardiovascular death, myocardial infarction, and measures of quality of life and cost-effectiveness. The evaluation of long-term safety will include all-cause mortality, stroke, transient ischemic attack, and hospitalization for heart failure. Enrollment commenced in November 2011 and was completed in summer 2013. Conclusions RIVER-PCI is a novel, large-scale, international, randomized, double-blind, placebo-controlled clinical trial evaluating the role of ranolazine in the long-term medical management of patients with ICR post-PCI.</description><subject>Acetanilides - therapeutic use</subject><subject>Angina Pectoris - therapy</subject><subject>Cardiology</subject><subject>Cardiovascular</subject><subject>Coronary vessels</subject><subject>Double-Blind Method</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Female</subject><subject>Heart attacks</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Male</subject><subject>Mortality</subject><subject>Percutaneous Coronary Intervention</subject><subject>Piperazines - therapeutic use</subject><subject>Quality of Life</subject><subject>Ranolazine</subject><subject>Retreatment - statistics & numerical data</subject><subject>Treatment Outcome</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9ksFuEzEQhlcIREvhAbggS1zKYcPY63gdkJBQKBCpElGgvVqOd5Y4OOtge4PaE-_AG_IMPAAOaUlVJE6W7e-f3zP-i-IxhQEFKp4vB3qxHDCg1QDkAIDfKQ4pjOpS1JzfLQ4BgJWyhuqgeBDjMm8Fk-J-ccA4E5KBPCx-nUUkviVBd97pS9shsR1Z62SxS5F8s2mRD4xfrR0mJAE3Opre6WAvM-M7otuEgawxmD7pDn0fifHBdzpcZGG-2-RCGXxB3mC0n7Oga7Lb9ki7P9ZpgWS2t299IJO94znGiI7M_jGe-ph-fv8xvek8vnae3HAmx7PJ-cmsnI4nz0gKVruHxb1Wu4iPrtaj4uztyafx-_L0w7vJ-PVpaXglUjliOOe8ZXNAPWdVJalgAthIchgiYoN0xKEBQ4XIo52LVnCKQ6MNmlaOOKuOiuNd3XXwX3uMSa1sNOjc7rmKckFlLQUbZvTpLXTp-5BHlKkhr6WUNa0yRXeUCT7GgK1aB7vKDSsKahsJtVQ5EmobCQVS5UhkzZOryv18hc1fxXUGMvByB2AexcZiUNHk3zfY2IAmqcbb_5Z_dUttnO2s0e4LXmDcd6EiU6A-bjO5jSStAIZMQvUbWlrjDA</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>Weisz, Giora, MD</creator><creator>Farzaneh-Far, Ramin, MD</creator><creator>Ben-Yehuda, Ori, MD</creator><creator>DeBruyne, Bernard, MD</creator><creator>Montalescot, Gilles, MD, PhD</creator><creator>Lerman, Amir, MD</creator><creator>Mahmud, Ehtisham, MD</creator><creator>Alexander, Karen P., MD</creator><creator>Ohman, E. Magnus, MD</creator><creator>White, Harvey D., DSc</creator><creator>Olmsted, Ann, PhD</creator><creator>Walker, Gennyne A., PhD</creator><creator>Stone, Gregg W., MD</creator><general>Mosby, Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20131201</creationdate><title>Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post–Percutaneous Coronary Intervention (RIVER-PCI) trial</title><author>Weisz, Giora, MD ; Farzaneh-Far, Ramin, MD ; Ben-Yehuda, Ori, MD ; DeBruyne, Bernard, MD ; Montalescot, Gilles, MD, PhD ; Lerman, Amir, MD ; Mahmud, Ehtisham, MD ; Alexander, Karen P., MD ; Ohman, E. Magnus, MD ; White, Harvey D., DSc ; Olmsted, Ann, PhD ; Walker, Gennyne A., PhD ; Stone, Gregg W., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-92eb44f2b0eab233816260298405eeede1940d0c166000b6f641e5cacecf89423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acetanilides - therapeutic use</topic><topic>Angina Pectoris - therapy</topic><topic>Cardiology</topic><topic>Cardiovascular</topic><topic>Coronary vessels</topic><topic>Double-Blind Method</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Female</topic><topic>Heart attacks</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Male</topic><topic>Mortality</topic><topic>Percutaneous Coronary Intervention</topic><topic>Piperazines - therapeutic use</topic><topic>Quality of Life</topic><topic>Ranolazine</topic><topic>Retreatment - statistics & numerical data</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weisz, Giora, MD</creatorcontrib><creatorcontrib>Farzaneh-Far, Ramin, MD</creatorcontrib><creatorcontrib>Ben-Yehuda, Ori, MD</creatorcontrib><creatorcontrib>DeBruyne, Bernard, MD</creatorcontrib><creatorcontrib>Montalescot, Gilles, MD, PhD</creatorcontrib><creatorcontrib>Lerman, Amir, MD</creatorcontrib><creatorcontrib>Mahmud, Ehtisham, MD</creatorcontrib><creatorcontrib>Alexander, Karen P., MD</creatorcontrib><creatorcontrib>Ohman, E. Magnus, MD</creatorcontrib><creatorcontrib>White, Harvey D., DSc</creatorcontrib><creatorcontrib>Olmsted, Ann, PhD</creatorcontrib><creatorcontrib>Walker, Gennyne A., PhD</creatorcontrib><creatorcontrib>Stone, Gregg W., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weisz, Giora, MD</au><au>Farzaneh-Far, Ramin, MD</au><au>Ben-Yehuda, Ori, MD</au><au>DeBruyne, Bernard, MD</au><au>Montalescot, Gilles, MD, PhD</au><au>Lerman, Amir, MD</au><au>Mahmud, Ehtisham, MD</au><au>Alexander, Karen P., MD</au><au>Ohman, E. Magnus, MD</au><au>White, Harvey D., DSc</au><au>Olmsted, Ann, PhD</au><au>Walker, Gennyne A., PhD</au><au>Stone, Gregg W., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post–Percutaneous Coronary Intervention (RIVER-PCI) trial</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>166</volume><issue>6</issue><spage>953</spage><epage>959.e3</epage><pages>953-959.e3</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Background Incomplete revascularization (ICR) after percutaneous coronary intervention (PCI) is common and is associated with increased rates of rehospitalization, revascularization, and mortality. Adjunctive pharmacotherapy with ranolazine, an inhibitor of the late sodium current with anti-ischemic properties, may be effective in reducing recurrent events after PCI in patients with ICR. Trial Design RIVER-PCI is a phase 3, randomized, double-blind, placebo-controlled, international event-driven clinical trial evaluating the efficacy of ranolazine in patients with a history of chronic angina and ICR after PCI. Approximately 2,600 participants with ICR post-PCI will be randomized in a 1:1 ratio to ranolazine or matched placebo within 14 days of an index PCI. The primary end point of the trial is time to the first occurrence of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization. Participants will be followed up for a minimum of 1 year and until at least 720 confirmed primary end point events have occurred. Secondary end points include sudden cardiac death, cardiovascular death, myocardial infarction, and measures of quality of life and cost-effectiveness. The evaluation of long-term safety will include all-cause mortality, stroke, transient ischemic attack, and hospitalization for heart failure. Enrollment commenced in November 2011 and was completed in summer 2013. Conclusions RIVER-PCI is a novel, large-scale, international, randomized, double-blind, placebo-controlled clinical trial evaluating the role of ranolazine in the long-term medical management of patients with ICR post-PCI.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>24268208</pmid><doi>10.1016/j.ahj.2013.08.004</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8703 |
| ispartof | The American heart journal, 2013-12, Vol.166 (6), p.953-959.e3 |
| issn | 0002-8703 1097-6744 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1461878625 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Acetanilides - therapeutic use Angina Pectoris - therapy Cardiology Cardiovascular Coronary vessels Double-Blind Method Enzyme Inhibitors - therapeutic use Female Heart attacks Hospitalization - statistics & numerical data Humans Male Mortality Percutaneous Coronary Intervention Piperazines - therapeutic use Quality of Life Ranolazine Retreatment - statistics & numerical data Treatment Outcome |
| title | Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post–Percutaneous Coronary Intervention (RIVER-PCI) trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T10%3A34%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20ranolazine%20in%20patients%20with%20incomplete%20revascularization%20after%20percutaneous%20coronary%20intervention:%20Design%20and%20rationale%20of%20the%20Ranolazine%20for%20Incomplete%20Vessel%20Revascularization%20Post%E2%80%93Percutaneous%20Coronary%20Intervention%20(RIVER-PCI)%20trial&rft.jtitle=The%20American%20heart%20journal&rft.au=Weisz,%20Giora,%20MD&rft.date=2013-12-01&rft.volume=166&rft.issue=6&rft.spage=953&rft.epage=959.e3&rft.pages=953-959.e3&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/j.ahj.2013.08.004&rft_dat=%3Cproquest_cross%3E1461878625%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1547888713&rft_id=info:pmid/24268208&rft_els_id=1_s2_0_S0002870313005280&rfr_iscdi=true |